Protein arginine methyltransferases and cancer

By Yanzhong Yang, M. Bedford. Nature Reviews. Cancer, 2012

1,043 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/66998eec5a82a440fe3bc4ade522fd72d4bcea8e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC (2017, background): “Among them, the overexpression of PRMT1 has been observed in lung, breast, bladder, colon, and prostate cancer and leukemia [29].”
PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP (2015, background): “Accumulated evidence has indicated that methylation of arginine and lysine residues plays an important role in the regulation of many biological processes like phosphorylation does, and its deregulation is almost certainly involved in human tumorigenesis [14, 35-37].”
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing (2015, background): “The relevance of PRMT1 inhibition in cancer therapies is summarized in reviews 466 (Greenblatt and Nimer, 2014; Yang and Bedford, 2013).”
Arginine Methylation: The Coming of Age. (2017, background): “Arginine methylation has also been shown to facilitate the resolution of R-loops via TDRD3 and TOP3B, which maintain genomic stability (Yang et al., 2014).”
PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents (2015, background): “Indeed, dysregulation of arginine and lysine methyltransferases have frequently been observed in human cancer [38–43], and these enzymes are now considered as emergent targets for anti-cancer drug development [14, 39, 44].”
Methylation multiplicity and its clinical values in cancer (2021, neutral): “57).”